XML 51 R35.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration, License, and Other Agreements - Amounts Recognized In Statement of Operations with Sanofi (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 2,294,000 | $ 1,743,700 | $ 6,074,200 | $ 4,694,100
Research and development expense | (684,600) | (526,000) | (1,990,500) | (1,897,600)
Regeneron's share of profits in connection with commercialization of antibodies | Sanofi Collaboration Agreement, Antibody |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 212,800 | 94,200 | 555,600 | 105,200
Sales-based milestone earned | Sanofi Collaboration Agreement, Antibody |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 50,000 | 0 | 50,000 | 0
Reimbursement for manufacturing of commercial supplies | Sanofi Collaboration Agreement, Antibody |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 94,300 | 85,400 | 275,000 | 143,800
Reimbursement for manufacturing of commercial supplies | Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 900 | 0 | 6,000 | 0
Reimbursement of research and development expenses | Sanofi Collaboration Agreement, Antibody |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Reduction of Research and development expense | 45,500 | 60,200 | 174,400 | 216,500
Reimbursement of research and development expenses | Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Reduction of Research and development expense | 49,800 | 38,000 | 136,700 | 120,900
Regeneron's obligation for its share of Sanofi research and development expenses | Sanofi Collaboration Agreement, Antibody |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Research and development expense | (17,500) | (10,200) | (59,100) | (29,800)
Reimbursement of commercialization-related expenses | Sanofi Collaboration Agreement, Antibody |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Reduction of Selling, general, and administrative expense | 83,200 | 111,600 | 260,400 | 349,300
Reimbursement of commercialization-related expenses | Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Reduction of Selling, general, and administrative expense | 14,500 | 3,000 | 39,200 | 7,000
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits | Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Cost of goods sold | (31,500) | (20,100) | (86,500) | (51,500)
Amounts recognized in connection with up-front payments received | Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Other operating income | 20,000 | 18,500 | 57,000 | 73,800
Outside United States | Regeneron's share of profits in connection with commercialization of antibodies | Sanofi Collaboration Agreement, Immuno-oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ (4,700) | $ (4,600) | $ (17,300) | $ (16,200)

X
- Definition Reimbursement Of Research And Development Expense + References No definition available. + Details
Name: | regn_ReimbursementOfResearchAndDevelopmentExpense
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reimbursement Of Selling, General And Administrative Expense + References No definition available. + Details
Name: | regn_ReimbursementOfSellingGeneralAndAdministrativeExpense
Namespace Prefix: | regn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_OtherOperatingIncome
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ShareOfProfitLossesInConnectionWithCommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementAntibodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_SalesBasedMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementForManufacturingOfCommercialSuppliesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=regn_SanofiCollaborationAgreementImmunooncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementOfResearchAndDevelopmentExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_RegeneronsShareOfResearchAndDevelopmentExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_ReimbursementOfCommercializationRelatedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_SanofisShareofLibtayoU.S.GrossProfitsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=regn_AmountsRecognizedInConnectionWithUpFrontPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |